The study revealed an upregulation of immunosuppressive features, such as CTLA-4 and PD-1, on CD4+CXCR5−FOXP3+ T cells in treatment-naïve CHB patients and in patients with HBV-related hepatic failure compared to healthy controls. Here, PDCD1 is linked to liver failure.